262 related articles for article (PubMed ID: 36451063)
1. Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.
Saw SP; Ang MK; Tan DS
Curr Treat Options Oncol; 2022 Dec; 23(12):1721-1731. PubMed ID: 36451063
[TBL] [Abstract][Full Text] [Related]
2. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
Christopoulos P
Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
[TBL] [Abstract][Full Text] [Related]
3. Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
Nagasaka M; Ou SI
Lung Cancer (Auckl); 2023; 14():101-109. PubMed ID: 38111829
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
Buffoni L; Vavalà T; Novello S
Curr Treat Options Oncol; 2016 Oct; 17(10):54. PubMed ID: 27523606
[TBL] [Abstract][Full Text] [Related]
5. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
West HJ; Kim JY
JAMA Oncol; 2024 Feb; 10(2):249-255. PubMed ID: 38153722
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
Isaacs J; Stinchcombe TE
Drugs; 2022 Jun; 82(8):855-863. PubMed ID: 35596880
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
[TBL] [Abstract][Full Text] [Related]
8. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.
de Scordilli M; Michelotti A; Bertoli E; De Carlo E; Del Conte A; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806230
[TBL] [Abstract][Full Text] [Related]
10. Integration of New Systemic Adjuvant Therapies for Non-small Cell Lung Cancer: Role of the Surgeon.
Donington JS; Gitlitz B; Lim E; Opitz I; Kim YT; Altorki N
Ann Thorac Surg; 2023 Jun; 115(6):1544-1555. PubMed ID: 36174774
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for early-stage non-small cell lung cancer: A system review.
Gao J; Zhang C; Wei Z; Ye X
J Cancer Res Ther; 2023 Aug; 19(4):849-865. PubMed ID: 37675709
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.
John AO; Ramnath N
Oncologist; 2023 Sep; 28(9):752-764. PubMed ID: 37338126
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer.
Pirker R
Curr Opin Oncol; 2024 Jan; 36(1):24-28. PubMed ID: 37865822
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC.
Walia A; Prasad V
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9513-9515. PubMed ID: 37178425
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract][Full Text] [Related]
16. Perioperative Immunotherapy in Non-Small Cell Lung Cancer.
O'Brien J; Bodor JN
Curr Treat Options Oncol; 2023 Dec; 24(12):1790-1801. PubMed ID: 38091187
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer.
Chuang JC; Liang Y; Wakelee HA
Hematol Oncol Clin North Am; 2017 Feb; 31(1):31-44. PubMed ID: 27912832
[TBL] [Abstract][Full Text] [Related]
18. [Immunotherapy for lung cancer].
Ostoros G
Magy Onkol; 2017 Jun; 61(2):153-157. PubMed ID: 28585617
[TBL] [Abstract][Full Text] [Related]
19. Tackling the immunotherapy conundrum: advances and challenges for operable non-small-cell lung cancer treatment.
Attieh F; Chartouni A; Boutros M; Mouawad A; Kourie HR
Immunotherapy; 2023 Nov; 15(16):1415-1428. PubMed ID: 37671552
[TBL] [Abstract][Full Text] [Related]
20. Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations.
Sim JK; Choi J; Lee SY
Korean J Intern Med; 2023 Nov; 38(6):787-796. PubMed ID: 37939663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
